All
Breakthrough therapy designation granted to nemolizumab for pruritus
December 9th 2019The United States Food and Drug Administration has granted Galderma’s nemolizumab a Breakthrough Therapy Designation following phase 2 results which suggests the drug is a considerable alleviant for pruritus associated with prurigo nodularis.
40 years of champions in dermatology
December 4th 2019In the decades that Dermatology Times reporters have covered the specialty, we’ve had the pleasure of profiling the specialty’s champions. Some shared their professional accomplishments, while others revealed unknown aspects of their personal lives. Here just some of the interesting tidbits from years’ past.
Hackathon winners explore precision medicine
November 14th 2019By the end of a three-day weekend, five of the teams at Hacking Dermatology's 2019 Hackathon walked away with $5,000 each. Learn more about the collaboration that took place and the solutions each team developed to solve pressing problem areas in dermatology.
Interleukin-29 for inflammatory autoimmune diseases
October 29th 2019Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.